BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Peter Mueller, Ph.D., Executive Vice President of Global Research and
Development and Chief Scientific Officer, will retire after more than 10
years with the company. Dr. Mueller's retirement will be effective
October 31, 2014, following a planned transition period. Dr. Mueller
joined Vertex in 2003 as Chief Scientific Officer and Senior Vice
President, Drug Discovery and Innovation.
"Peter is a visionary who embodied Vertex's fearless pursuit of
transformational medicines," said Jeffrey Leiden, M.D., Ph.D., Chairman,
President and Chief Executive Officer of Vertex. "I thank Peter for his
leadership, innovation and dedication to Vertex over the past decade."
Jeffrey A. Chodakewitz, M.D., Vertex's Senior Vice President of Global
Medicines Development and Medical Affairs and Chief Medical Officer,
will continue to oversee all global clinical development programs and
other related functions and will now assume additional responsibility
for Regulatory Affairs and Global Patient Safety. Vertex expects to
appoint a Head of Global Research to oversee the company's drug
discovery efforts following Dr. Mueller's retirement.
About Vertex
Vertex is a global biotechnology company that aims to discover, develop
and commercialize innovative medicines so people with serious diseases
can lead better lives. In addition to our clinical development programs
focused on cystic fibrosis, Vertex has more than a dozen ongoing
research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and
development sites and commercial offices in the United States, Europe,
Canada and Australia. For four years in a row, Science magazine
has named Vertex one of its Top Employers in the life sciences. For
additional information and the latest updates from the company, please
visit www.vrtx.com.
Vertex's press releases are available at www.vrtx.com.
Special Note Regarding Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, the statements in the third paragraph of this press release.
While Vertex believes the forward-looking statements contained in this
press release are accurate, there are a number of factors that could
cause actual events or results to differ materially from those indicated
by such forward-looking statements. Those risks and uncertainties
include, among other things, the risks listed under Risk Factors in
Vertex's annual report and quarterly reports filed with the Securities
and Exchange Commission and available through the company's website at www.vrtx.com.
Vertex disclaims any obligation to update the information contained in
this press release as new information becomes available.
(VRTX-GEN)
Vertex Pharmaceuticals Incorporated
Media
Megan Pace
617-341-6992
mediainfo@vrtx.com
or
Investors
Michael
Partridge, 617-341-6108
or
Kelly Lewis, 617-961-7530
Source: Vertex Pharmaceuticals Incorporated
News Provided by Acquire Media
